[Economic analysis of neonatal screening for drepanocytosis in metropolitan France].
There is indisputable evidence that mortality and morbidity can be significantly reduced by programmes that screen newborns for sickle cell disease. But in the French epidemiological context, national decision regarding generalization of local screening programmes to all newborns must take into account economic considerations as at-risk populations represent, in most geographic areas, a few percent of the total population. Targeted screening can be considered but raises ethical and practical issues. In order to compare alternative screening strategies, a cost-effectiveness analysis has been performed. The analysis is based on a screening programme of newborns conducted in the south-eastern suburb of Paris. Strategies have been defined in terms of laboratory procedures (isoelectrofocalisation, electrophoresis on citrate agar, high pressure liquid chromatography, BIORAD technique,...) and methods for blood collection (dried paper, micro-tube). An evaluation of all the necessary costs have been performed for each strategy in the biochemistry laboratory in charge of the neonatal programme. Costs have been estimated from detailed observation of physical quantities of capital and labour involved in each case. Evolution of unit and marginal costs according to the level of annual production has been assessed. Effectiveness has been measured in terms of number of sickle cell cases detected. Screening of at-risk babies in Paris region would permit detection of 80 to 215 babies each year at a unit cost per case found varying from 1 to 2,800 US$ (according to hypothesis of prevalence). When compared with other programmes of prevention, results of selected screening of newborns in whole metropolitan France suggest that this action might be discussed by public health authorities.
Le Galès
C
C
Centre de Recherches en Economie de la Santé, INSERM U 357, CNRS UMR 99-32, Hôpital de Bicêtre, Le Kremlin-Bicêtre.
Galactéros
F
F
D000755:Anemia, Sickle Cell / Q000453:epidemiology*; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D015233:Models, Statistical; D015997:Neonatal Screening / Q000191:economics* / Q000379:methods; D012307:Risk Factors
Analyse économique du dépistage néonatal de la drépanocytose en France métropolitaine.